sera prognostics announces board elections and auditor ratification

Today, Sera Prognostics , Inc. (NASDAQ:SERA), a $60 million market cap company whose shares are trading near their 52-week low of $1.53, held its annual stockholders meeting via webcast. According to InvestingPro data, while the company maintains a strong cash position relative to debt, it faces challenges with rapid cash burn. The company reported that 66.2% of its eligible shares participated, totaling 24,314,265 shares. The meeting included the election of two directors and the ratification of its auditor.

Stockholders elected Jane F. Barlow, M.D., and Mansoor Raza Mirza, M.D., to the board as Class I directors. Each will serve a three-year term until the 2028 annual meeting. Barlow received 14,420,152 votes in favor, with 4,895,002 votes withheld. Mirza garnered 14,351,738 votes, with 4,963,416 votes withheld. Both nominees had 4,999,111 broker non-votes.

Additionally, stockholders ratified Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2025. The ratification was supported by 24,311,571 votes, with 2,691 votes against and 3 abstentions.

This information is based on a press release statement from Sera Prognostics.

In other recent news, Sera Prognostics reported its first-quarter 2025 earnings, revealing a narrower-than-expected loss with an EPS of -$0.20, compared to the forecasted -$0.27. However, the company’s revenue came in at $38,000, significantly below the anticipated $200,000, marking a modest start from zero revenue in the same quarter last year. This earnings report highlights Sera Prognostics’ ongoing challenges in scaling sales despite effective cost management. The company is focusing on commercialization efforts and expanding its market presence, particularly through Medicaid and specific geographic regions. Additionally, Sera Prognostics announced the appointment of Lee Anderson as the new Chief Commercial Officer, bringing over three decades of healthcare leadership experience to drive the commercial expansion of the company’s products. Anderson’s past roles at Genomic Health and Exact Sciences (NASDAQ:EXAS) were marked by significant revenue growth and successful product launches. The company remains optimistic about the potential impact of Anderson’s appointment on sales strategies and market presence. These developments reflect Sera Prognostics’ strategic focus on enhancing its commercial roadmap and expanding its footprint in the healthcare diagnostics sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.